Buscar
Congreso SOLACI
HomeInternational CongressesACC 2022

ACC 2022

Ver Categoría
Acute coronary syndromes

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two...
solaci -
Ver más
Other

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device....
solaci -
Ver más
Antiplatelet

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...
solaci -
Ver más
Antiplatelet

ACC 2022 | BENTRACIMAB

This study was presented in phase 2, in a healthy population between 50 and 80 years of...
solaci -
Ver más
Acute coronary syndromes

ACC 2022 | COMPLETE

Percutaneous coronary intervention improves angina related quality of life in AMI patients with multivessel disease. The COMPLETE...
solaci -
Ver más
Acute coronary syndromes

ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous...
solaci -
Ver más
Coronary Disease

ACC 2022 | IVVE

This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure.  It included...
solaci -
Ver más
Acute coronary syndromes

ACC 2022 | PROMPT-HF

Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad